十一酸睾酮(AVEED)治疗男性睾酮缺乏的初始临床经验
该研究回顾了本中心2014年7月1日至2016年8月1日接受十一酸睾酮750 mg治疗的147例男性,平均年龄63.2岁。治疗后总睾酮和游离睾酮谷值均值较基线升高(P均<.001),66.0%患者报告症状改善,20.4%停药;未发生卒中、心肌梗死、死亡或新发前列腺癌。
要点
- 147例接受超过2次注射的男性中,66.0%报告症状改善,20.4%停药。
- 总睾酮谷值均值从305 ng/dL升至413.2 ng/dL,游离睾酮从0.69 ng/dL升至0.81 ng/dL(P均<.001)。
- 3例(2%)出现注射后短暂咳嗽,均无需干预;无卒中、心肌梗死、死亡或新发前列腺癌。
核心结论
- 该十一酸睾酮750 mg初始临床经验表明患者满意度和治疗持续性良好,安全性特征有利。
- 作者认为部分个体的最佳给药间隔可能短于10周。
研究设计与样本
- 单中心回顾性研究,纳入2014年7月1日至2016年8月1日在本中心接受十一酸睾酮750 mg治疗的男性。
- 通过结构化访谈和实验室评估评价临床反应,记录不良事件。
主要发现
- 147例接受超过2次注射的男性,平均年龄63.2岁;基线总睾酮均值305 ng/dL,游离睾酮均值0.69 ng/dL。
- 治疗期间总睾酮谷值均值413.2 ng/dL,游离睾酮谷值均值0.81 ng/dL(P均<.001)。
- 97/147例(66.0%)报告症状改善;30例(20.4%)停止治疗;34%报告下次注射前症状复发,通过缩短注射间隔和/或补充环戊丙酸睾酮处理。
- 平均血细胞比容从45.6%升至47.2%;平均PSA从1.7 ng/mL升至2.0 ng/mL。
- 3例(2%)注射后即刻出现短暂咳嗽,均无需干预;无卒中、心肌梗死、死亡或新发前列腺癌。
临床怎么用
- 作者认为部分个体的最佳给药间隔可能短于10周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report our initial experiences with testosterone undecanoate (TU 750) mg (AVEED) in men with testosterone deficiency. METHODS: All patients receiving TU 750 mg at our center between July 1, 2014, and August 1, 2016, were identified. Clinical response was assessed through structured interviews and laboratory evaluations. Adverse events were documented, including increase in prostate specific antigen (PSA), increase in hematocrit (Hct), and the development of postinjection cough. RESULTS: More than 2 injections were received by 147 men, with mean age 63.2 years. Mean baseline total testosterone (T) and free T were 305 ng/dL and 0.69 ng/dL, respectively. Nadir mean results during treatment were higher for total and free T, at 413.2 ng/dL and 0.81 ng/dL, respectively (P < .001 for each). Symptomatic improvement was reported by 97 of 147 patients (66.0%). Thirty patients (20.4%) discontinued therapy. Return of symptoms before the next injection was noted by 34%, managed by reduced interval between injections and/or supplemental injections of T cypionate. Three patients (2%) experienced transient cough immediately after TU injection, none requiring intervention. Mean Hct rose from 45.6% to 47.2%. Mean PSA rose from 1.7 ng/mL to 2.0 ng/mL. There were no strokes, myocardial infarctions, or deaths, and no new cases of prostate cancer. CONCLUSION: This initial clinical experience with TU 750 mg provides evidence for good patient satisfaction and persistence with treatment, together with a favorable safety profile. Optimal dosing may be less than 10 weeks for some individuals.
引用
- Krakowsky Y, Conners W, Davidson E, et al. Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States. Urology. 2017. PMID: 28735014. doi:10.1016/j.urology.2017.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。